RT Journal Article SR Electronic T1 Unusual SARS-CoV-2 intra-host diversity reveals lineages superinfection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.18.21263755 DO 10.1101/2021.09.18.21263755 A1 Filipe Zimmer Dezordi A1 Paola Cristina Resende A1 Felipe Gomes Naveca A1 Valdinete Alves do Nascimento A1 Victor Costa de Souza A1 Anna Carolina Dias Paixão A1 Luciana Appolinario A1 Renata Serrano Lopes A1 Ana Carolina da Fonseca Mendonça A1 Alice Sampaio Barreto da Rocha A1 Taina Moreira Martins Venas A1 Elisa Cavalcante Pereira A1 Richard Steiner Salvato A1 Tatiana Schäffer Gregianini A1 Leticia Garay Martins A1 Felicidade Mota Pereira A1 Darcita Buerger Rovaris A1 Sandra Bianchini Fernandes A1 Rodrigo Ribeiro-Rodrigues A1 Thais Oliveira Costa A1 Joaquim Cesar Sousa, Jr A1 Fabio Miyajima A1 Edson Delatorre A1 Tiago Gräf A1 Gonzalo Bello A1 Marilda Mendonça Siqueira A1 Gabriel da Luz Wallau A1 on behalf of Fiocruz COVID-19 Genomic Surveillance Network YR 2021 UL http://medrxiv.org/content/early/2021/09/23/2021.09.18.21263755.abstract AB The SARS-CoV-2 has infected almost 200 million people worldwide by July 2021 and the pandemic has been characterized by infection waves of viral lineages showing distinct fitness profiles. The simultaneous infection of a single individual by two distinct SARS-CoV-2 lineages provides a window of opportunity for viral recombination and the emergence of new lineages with differential phenotype. Several hundred SARS-CoV-2 lineages are currently well characterized but two main factors have precluded major coinfection/codetection analysis thus far: i) the low diversity of SARS-CoV-2 lineages during the first year of the pandemic which limited the identification of lineage defining mutations necessary to distinguish coinfecting viral lineages; and the ii) limited availability of raw sequencing data where abundance and distribution of intrasample/intrahost variability can be accessed. Here, we have put together a large sequencing dataset from Brazilian samples covering a period of 18 May 2020 to 30 April 2021 and probed it for unexpected patterns of high intrasample/intrahost variability. It enabled us to detect nine cases of SARS-CoV-2 coinfection with well characterized lineage-defining mutations. In addition, we matched these SARS-CoV-2 coinfections with spatio-temporal epidemiological data confirming their plausibility with the co-circulating lineages at the timeframe investigated. These coinfections represent around 0.61% of all samples investigated. Although our data suggests that coinfection with distinct SARS-CoV-2 lineages is a rare phenomenon, it is likely an underestimation and coinfection rates warrants further investigation.DATA SUMMARY The raw fastq data of codetection cases are deposited on gisaid.org and correlated to gisaid codes: EPI_ISL_1068258, EPI_ISL_2491769, EPI_ISL_2491781, EPI_ISL_2645599, EPI_ISL_2661789, EPI_ISL_2661931, EPI_ISL_2677092, EPI_ISL_2777552, EPI_ISL_3869215. Supplementary data are available on https://doi.org/10.6084/m9.figshare.16570602.v1. The workflow code used in this study is publicly available on: https://github.com/dezordi/IAM_SARSCOV2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support was provided by FAPEAM (PCTIEmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude - REGESAM); Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Ministerio da Saude - MS/FNDCT/SCTIE/Decit (grants 402457/2020-9 and 403276/2020-9); Inova Fiocruz/Fundacao Oswaldo Cruz (Grants VPPCB-007-FIO-18-2-30 and VPPCB-005- FIO-20-2-87) and INCT-FCx (465259/2014-6). This work was also supported by the Pan American Health Organization, Brazil Country Office. FGN, GLW and GB are supported by the CNPq through their productivity research fellowships (306146/2017-7, 303902/2019, 302317/2017-1, respectively).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Aggeu Magalhaes Institute Ethical Committee - CAAE 32333120.4.0000.5190, FIOCRUZ-IOC Ethics Committee (68118417.6.0000.5248 and CAAE 32333120.4.0000.5190), the Brazilian Ministry of Health SISGEN (A1767C3). Moreover, it was approved by the Ethics Committee of Amazonas State University (no. 25430719.6.0000.5016), which waived signed informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw fastq data of codetection cases are deposited on gisaid.org and correlated to gisaid codes: EPI_ISL_1068258, EPI_ISL_2491769, EPI_ISL_2491781, EPI_ISL_2645599, EPI_ISL_2661789, EPI_ISL_2661931, EPI_ISL_2677092, EPI_ISL_2777552, EPI_ISL_3869215. Supplementary data are available on https://doi.org/10.6084/m9.figshare.16570602.v1. The workflow code used in this study is publicly available on: https://github.com/dezordi/IAM_SARSCOV2. https://doi.org/10.6084/m9.figshare.16570602.v1 https://github.com/dezordi/IAM_SARSCOV2